English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Ovarian damage following cancer therapy is dependent on age at treatment as well as the type of therapeutic exposures. Older age and exposure to higher doses of alkylating agents and higher doses of radiation to the ovary are associated with a greater likelihood of ovarian failure. Acute loss of ovarian function during or shortly following treatment is relatively uncommon in females treated during childhood and adolescence but can be seen following myeloablative, alkylator-based cytoreduction (e.g., busulfan and cyclophosphamide) for stem cell transplant and following direct ovarian radiation with doses &gt;10 Gy. For survivors who retain normal ovarian function after cancer therapy, there is an increased risk of premature menopause later in life. The risk factors associated with an early menopause include exposure to high doses of alkylating agents and abdomino-pelvic radiation.

Maintenance of Ovarian Function and Risk of Premature Menopause Related to Cancer Treatment